Dr. Michelle R. Boyce, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- St. Louis College of Physicians and Surgeons (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 593
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: St. Louis College of Physicians and Surgeons
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
MO license 2018008052 · IA license MD-43231 · KS license 9407922 · NE license 29823
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Harrison County Community Hospital Bethany, MO
Medical groups
- Moyes Eye Center, P.c. (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 593
- Services billed
- 2,038
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Removal of cataract with insertion of prosthetic lens | 418 | 242 |
| Measurement of corneal curvature and depth of eye | 399 | 274 |
| Ct scan of cornea | 212 | 170 |
| New patient office or other outpatient visit, 45-59 minutes | 192 | 192 |
| Established patient office or other outpatient visit, 30-39 minutes | 150 | 136 |
| Established patient office or other outpatient visit, 20-29 minutes | 149 | 103 |
| Established patient complete exam of visual system | 148 | 143 |
| Established patient problem focused exam of visual system | 146 | 91 |
| Removal of recurring cataract in lens capsule using a laser | 115 | 112 |
| New patient complete exam of visual system | 109 | 109 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Kansas City, MO | 889 |
| Tobramycin | 502 |
| Fluorometholone Other prescribers in Kansas City, MO | 158 |
| Ketorolac Tromethamine Other prescribers in Kansas City, MO | 71 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Kansas City, MO | 69 |
| Ofloxacin Other prescribers in Kansas City, MO | 67 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Kansas City, MO | 66 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Kansas City, MO | 59 |
| Doxycycline Hyclate Other prescribers in Kansas City, MO | 43 |
| Timolol Maleate Other prescribers in Kansas City, MO | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 13 payments worth $417 in total to this clinician.
| Sun Pharmaceutical Industries Inc. | $125 |
|---|---|
| Alcon Vision LLC | $96.00 |
| Dompe US, Inc. | $84.52 |
| Glaukos Corporation | $78.18 |
| AbbVie Inc. | $33.25 |
| Food and Beverage | $417 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $4,794 in research payments for these studies, mostly to the institutions running them.
- Follow-up of Eyes that Received Epithelium-on Corneal Collagen Cross-Linking Treatment in Study GLK-202-12
Glaukos Corporation - A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus
Glaukos Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.